PLYMOUTH, Mich.--(BUSINESS WIRE)--
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage
biopharmaceutical company focused on developing and commercializing
first-in-class, oral, low-density lipoprotein cholesterol (LDL-C)
lowering therapies for the treatment of hypercholesterolemia, today
announced that the company has been added to the NASDAQ Biotechnology
Index (NASDAQ: NBI) effective prior to the market open on December 23,
2013. The Index is designed to track the performance of a set of
securities listed on The NASDAQ Stock Market(R) (NASDAQ(R)) that are
classified as either biotechnology or pharmaceutical according to the
Industry Classification Benchmark (ICB). This is the most recent index
to which the company has been added in 2013. The company is also
included in the Russell Global, 3000, 2000, and Microcap indices, and
the MSCI Global Micro Cap indices.
About Esperion Therapeutics
Esperion Therapeutics, Inc. is a biopharmaceutical company focused on
the research, development and commercialization of therapies for the
treatment of patients with elevated levels of low-density lipoprotein
cholesterol (LDL-C) and other cardiometabolic risk factors. ETC-1002,
Esperion's lead product candidate, is a unique, first-in-class, orally
available, once-daily small molecule therapy designed to lower levels of
LDL-C and to avoid side effects associated with existing LDL-C lowering
therapies. ETC-1002 is targeted for statin intolerant patients with
elevated levels of LDL-C. Esperion has completed seven clinical studies
to date, including four Phase 2a studies, and has initiated a robust
Phase 2b clinical program. For more information, please visit www.esperion.com.
Forward Looking Statements
This press release contains forward-looking statements that are made
pursuant to the safe harbor provisions of the federal securities laws,
including statements regarding the therapeutic potential of ETC-1002.
Any statements contained in this press release that are not statements
of historical fact may be deemed to be forward-looking statements.
Forward-looking statements involve risks and uncertainties that could
cause Esperion's actual results to differ significantly from those
projected, including, without limitation, the risk that unanticipated
developments could interfere with the development (and
commercialization) of ETC-1002, as well as other risks detailed in
Esperion's filings with the Securities and Exchange Commission,
including our Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 6, 2013. You are cautioned not to
place undue reliance on the forward-looking statements, which speak only
as of the date of this release. Esperion disclaims any obligation or
undertaking to update or revise any forward-looking statements contained
in this press release, other than to the extent required by law.
Denise Powell, 510-703-9491
Source: Esperion Therapeutics, Inc.
News Provided by Acquire Media